Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cartesian Therapeutics Announced Topline Results From Its Phase 2B Trial Of Descartes-08 In Patients With Generalized Myasthenia Gravis, Trial Met The Primary Endpoint With Statistical Significance

Author: Benzinga Newsdesk | July 02, 2024 06:32am

Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo.
Deep and durable responses up to at least six months observed in patients treated with Descartes-08.
Safety profile continues to support outpatient administration.
Company expects to hold End-of-Phase 2 meeting with the FDA by year-end.

Posted In: RNAC